Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.

Abstract

INTRODUCTION:

Migraine is a leading cause of years lived with disability and preventive strategies represent a mainstay to reduce health-related disability and improve quality of life of migraine patients. Until a few years ago, migraine prevention was based on drugs developed for other clinical indications and relocated in the migraine therapeutic armamentarium, characterized by unfavorable tolerability profiles. The advent of monoclonal antibodies against Calcitonin Gene-Related Peptide (CGRP) and gepants, CGRP receptor antagonists, has been a turning point in migraine prevention owing to advantageous efficacy, safety and tolerability profiles.Nevertheless, while in an ideal scenario a drug characterized by significant greater efficacy and tolerability compared to existing therapeutic strategies should be adopted as a first-line treatment, cost-effectiveness analyses available for monoclonal antibodies against CGRP pathway tend to limit their administration to more severe migraine phenotypes.

AREAS COVERED:

The present narrative review aims to provide a critical appraisal of phase II and III CGRP-mAbs and gepants trials to analyze their use in clinical practice.

EXPERT OPINION:

Despite monoclonal antibodies against CGRP pathway and gepants can be undoubtedly considered top-of-the-range treatments, there are still issues deserving to be addressed in the coming years as the risk of off-target effects as well as their economic sustainability based on the considerable migraine burden.

• Authors: Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, Francesca Trojsi, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo
• Journal: Expert opinion on emerging drugs (Expert Opin Emerg Drugs) Vol. 28 Issue 2 Pg. 79-96 (12 2023) ISSN: 1744-7623 [Electronic] England
• PMID: 37185047 (Publication Type: Review, Journal Article)

Chemical References

• Calcitonin Gene-Related Peptide
• Calcitonin Gene-Related Peptide Receptor Antagonists
• Antibodies, Monoclonal
• Pharmaceutical Preparations

Topics

• Humans
• Calcitonin Gene-Related Peptide (metabolism)
• Calcitonin Gene-Related Peptide Receptor Antagonists (pharmacology, therapeutic use)
• Antibodies, Monoclonal (adverse effects)
• Pharmaceutical Preparations
• Quality of Life
• Migraine Disorders (drug therapy, prevention & control)